BioMarin Pharmaceutical (BMRN) said Friday it will acquire Amicus Therapeutics (FOLD) for $4.8 billion in a deal that adds two rare disease drugs to its portfolio. In premarket trades on the stock market today, Amicus stock catapulted 29.8% to 14.13, just under the takeover price of $14.50 per share. The biotech stock is highly rated and has climbed roughly 94%…
New Delhi: States sought greater special assistance for capital investments, and enhanced support to compensate for revenue loss due to...
New Delhi: India is likely to be represented by minister of electronics and IT Ashwini Vaishnaw at a key meet...
As Venezuelan detainee Diógenes Angulo left a prison in San Francisco de Yare after a year and five months behind...
Thousands of people marched in Minneapolis Saturday to protest the fatal shooting of a woman by a federal immigration officer there and...
The U.S. has launched another round of retaliatory strikes against the Islamic State in Syria following last month’s ambush that killed two...
When Lloyd Blankfein was CEO of Goldman Sachs, thousands of newly minted graduates from top universities joined the ranks of...
The first and only national digital and print magazine that connects individuals, families, and businesses to Fee-Only financial advisers, accountants, attorneys and college guidance counselors.
